Get started
DAIICHI SANKYO COMPANY LIMITEDDAIICHI SANKYO COMPANY LIMITEDDAIICHI SANKYO COMPANY LIMITED

DAIICHI SANKYO COMPANY LIMITED

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

4568 chart


Full chart

4568 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪8.50 T‬ JPY
Dividend yield (indicated)
1.35%
Price to earnings Ratio (TTM)
34
Basic EPS (TTM)
131 JPY
Net income (FY)
‪200.73 B‬ JPY
Revenue (FY)
‪1.60 T‬ JPY
Shares float
‪1.63 B‬
Beta (1Y)
0.96

Employees


Employees (FY)
‪18.73 K‬
Change (1Y)
‪+1.29 K‬ +7.40%
Revenue / Employee (1Y)
‪565.12 K‬ JPY
Net income / Employee (1Y)
‪70.82 K‬ JPY

About DAIICHI SANKYO COMPANY LIMITED


Sector
Health Technology
CEO
Sunao Manabe
Headquarters
Tokyo
Website
daiichisankyo.co.jp
Founded
2005
ISIN
JP3475350009
FIGI
BBG000BWPMB8
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

4568 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 4568 is 4,435 JPY — it has decreased by −1.07% in the past 24 hours. Watch DAIICHI SANKYO COMPANY LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange DAIICHI SANKYO COMPANY LIMITED stocks are traded under the ticker 4568.
4568 stock has fallen by −3.59% compared to the previous week, the month change is a −8.80% fall, over the last year DAIICHI SANKYO COMPANY LIMITED has showed a 10.88% increase.
We've gathered analysts' opinions on DAIICHI SANKYO COMPANY LIMITED future price: according to them, 4568 price has a max estimate of 7,600.00 JPY and a min estimate of 5,600.00 JPY. Watch 4568 chart and read a more detailed DAIICHI SANKYO COMPANY LIMITED stock forecast: see what analysts think of DAIICHI SANKYO COMPANY LIMITED and suggest that you do with its stocks.
4568 reached its all-time high on Aug 30, 2024 with the price of 6,257 JPY, and its all-time low was 389 JPY and was reached on Oct 11, 2012. View more price dynamics on 4568 chart.
See other stocks reaching their highest and lowest prices.
4568 stock is 1.53% volatile and has beta coefficient of 0.96. Track DAIICHI SANKYO COMPANY LIMITED stock price on the chart and check out the list of the most volatile stocks — is DAIICHI SANKYO COMPANY LIMITED there?
Today DAIICHI SANKYO COMPANY LIMITED has the market capitalization of ‪8.41 T‬, it has decreased by −2.86% over the last week.
Yes, you can track DAIICHI SANKYO COMPANY LIMITED financials in yearly and quarterly reports right on TradingView.
DAIICHI SANKYO COMPANY LIMITED is going to release the next earnings report on Jan 29, 2025. Keep track of upcoming events with our Earnings Calendar.
4568 earnings for the last quarter are 32.23 JPY per share, whereas the estimation was 24.52 JPY resulting in a 31.42% surprise. The estimated earnings for the next quarter are 28.94 JPY per share. See more details about DAIICHI SANKYO COMPANY LIMITED earnings.
DAIICHI SANKYO COMPANY LIMITED revenue for the last quarter amounts to ‪446.55 B‬ JPY, despite the estimated figure of ‪428.43 B‬ JPY. In the next quarter, revenue is expected to reach ‪472.96 B‬ JPY.
4568 net income for the last quarter is ‪61.29 B‬ JPY, while the quarter before that showed ‪85.38 B‬ JPY of net income which accounts for −28.22% change. Track more DAIICHI SANKYO COMPANY LIMITED financial stats to get the full picture.
DAIICHI SANKYO COMPANY LIMITED dividend yield was 1.05% in 2023, and payout ratio reached 47.76%. The year before the numbers were 0.62% and 52.67% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 24, 2024, the company has ‪18.73 K‬ employees. See our rating of the largest employees — is DAIICHI SANKYO COMPANY LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DAIICHI SANKYO COMPANY LIMITED EBITDA is ‪313.32 B‬ JPY, and current EBITDA margin is 15.62%. See more stats in DAIICHI SANKYO COMPANY LIMITED financial statements.
Like other stocks, 4568 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DAIICHI SANKYO COMPANY LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DAIICHI SANKYO COMPANY LIMITED technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DAIICHI SANKYO COMPANY LIMITED stock shows the sell signal. See more of DAIICHI SANKYO COMPANY LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.